Last reviewed · How we verify
Transdermal Testosterone
At a glance
| Generic name | Transdermal Testosterone |
|---|---|
| Also known as | transdermal group |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- COMPASS - COpenhagen MenoPAuSe Study (PHASE2)
- Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause (NA)
- Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males (PHASE1)
- Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance (PHASE4)
- Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency
- Testosterone Therapy in Castration Resistant Prostate Cancer (EARLY_PHASE1)
- Human Cerebral Blood Flow Regulation (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Testosterone CI brief — competitive landscape report
- Transdermal Testosterone updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI